COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 629: Articles 6281-6290  | Next

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A.-C., Goff, S. P., Sabo, Y., Yang, H., Chavez, A., Ho, D. D.
10.1101/2022.08.07.499047 — Posted: 2022-08-08
Severity Predictors of COVID-19 in SARS-CoV-2 Variant, Delta and Omicron Period; Single Center Study
Ogawa, F., Oi, Y., Honzawa, H., Misawa, N., Takeda, T., Kikuchi, Y., Fukui, R., Tanaka, K., Kano, D., Kato, H., Abe, T., Takeuchi, I.
10.1101/2022.08.06.22278449 — Posted: 2022-08-08
A Plagiarism Paperdemic - Plagiarism in infection journals in the era of COVID-19
Menshawey, R., Menshawey, E., Mitkees, A., Mahamud, B. A.
10.1101/2022.08.04.22278404 — Posted: 2022-08-08
Protein Geometry, Function and Mutation
Penner, R. C.
10.1101/2022.08.08.503157 — Posted: 2022-08-08
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75
Saito, A., Tamura, T., Zahradnik, J., Deguchi, S., Tabata, K., Kimura, I., Ito, J., Nasser, H., Toyoda, M., Nagata, K., Uriu, K., Kosugi, Y., Fujita, S., Yamasoba, D., Shofa, M., Begum, M. M., Oda, Y., Suzuki, R., Ito, H., Nao, N., Wang, L., Tsuda, M., Yoshimatsu, K., Yamamoto, Y., Nagamoto, T., Asakura, H., Nagashima, M., Sadamasu, K., Yoshimura, K., Ueno, T., Schreiber, G., Takaori-Kondo, A., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Shirakawa, K., Sawa, H., Irie, T., Takayama, K., Matsuno, K., Tanaka, S., Ikeda, T., Fukuhara, T., Sato, K.
10.1101/2022.08.07.503115 — Posted: 2022-08-08
A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations
Ou, J., Lewandowski, E., Hu, Y., Lipinski, A., Morgan, R., Jacobs, L., Zhang, X., Bikowitz, M., Langlais, P., Tan, H., Wang, J., Chen, Y., Choy, J. S.
10.1101/2022.08.06.503039 — Posted: 2022-08-08
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Moghadasi, S. A., Heilmann, E., Moraes, S. N., Kearns, F. L., von Laer, D., Amaro, R. E., Harris, R.
10.1101/2022.08.07.503099 — Posted: 2022-08-08
Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity
Hirota, M., Tamai, M., Yukawa, S., Taira, N., Matthews, M. M., Toma, T., Seto, Y., Yoshida, M., Toguchi, S., Miyagi, M., Mori, T., Tomori, H., Tamai, O., Kina, M., Sakihara, E., Yamashiro, C., Miyagi, M., Tamaki, K., Wolf, M., Collins, M. K., Kitano, H., Ishikawa, H.
10.1101/2022.08.08.503075 — Posted: 2022-08-08
The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2, Necroptosis, Pyroptosis and Panoptosis
Schifanella, L., Anderson, J., Wieking, G., Southern, P. J., Antinori, S., Galli, M., Corbellino, M., Lai, A., Klatt, N., Schacker, T., Haase, A. T.
10.1101/2022.08.06.503050 — Posted: 2022-08-08
Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: allosteric communications between and within viral and human proteins
Barozi, V., Edkins, A. L., Tastan Bishop, O.
10.1101/2022.08.06.503019 — Posted: 2022-08-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).